Quadrant Clinical Care (QCCA) has defended its use of a blood filtering device designed to assist cancer patients, following recent scrutiny. The device, developed by ExThera, is approved for use in the European Union, provisionally in the United States for treating COVID-19 patients, and is undergoing trials as a pancreatic cancer therapy under the supervision of the US Food and Drug Administration (FDA). It has also been authorised for use in Antigua and Barbuda.
In a statement, QCCA highlighted the safety and potential benefits of the device, which has been used in thousands of treatments worldwide. The clinic said the filter is effective in removing bloodborne pathogens, including Circulating Tumour Cells (CTCs) found in cancer patients. It added that all procedures were conducted by trained medical professionals in line with international best practices.
The clinic’s president and CEO, Tom Pontzius, said patients were fully informed about the therapy’s safety record, its effectiveness, and potential risks. He described the treatment as offering “potential benefits to terminal cancer patients” and said patients were treated “with care and respect.”
The statement also addressed criticisms raised in the media about patient care, with QCCA insisting many of the claims were inaccurate. Pontzius said the clinic could not comment on individual cases due to privacy concerns but expressed sympathy for families who had lost loved ones to late-stage cancer.
“Individual perceptions should not be mistaken for fact-based medical judgment,” he said.
QCCA reaffirmed its confidence in the device, describing it as a promising therapy for cancer patients. It said the clinic remained committed to providing innovative treatment options while maintaining high standards of care.
Advertise with the mоѕt vіѕіtеd nеwѕ ѕіtе іn Antigua!
We offer fully customizable and flexible digital marketing packages.
Contact us at [email protected]
